FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012138315> ?p ?o ?g. }

• W2012138315 endingPage "93.e1" @default.
• W2012138315 startingPage "84" @default.
• W2012138315 abstract "To evaluate the short-term efficacy and safety of intravitreal bevacizumab for the treatment of myopic choroidal neovascularization (CNV).Prospective, nonrandomized, interventional case series.Twenty eyes from 20 patients with CNV secondary to pathologic myopia participated in this prospective nonrandomized interventional case series. All patients were scheduled for three monthly intravitreal bevacizumab 1.25 mg injections. Early Treatment Diabetic Retinopathy Study best-corrected visual acuity (BCVA), foveal center thickness (FCT) on optical coherence tomography (OCT), and fluorescein angiographic findings were examined before and after treatment. Patients were followed up for 12 months.The mean BCVA (+/- standard deviation [SD]) at baseline was 24.8 (+/- 11.86) letters (Snellen equivalent: 20/80). At 12 months after treatment, the mean BCVA (+/- SD) improved significantly (P = .000001) to 43 (+/- 12.38) letters (Snellen equivalent: 20/35). At 12 month follow-up, BCVA improved 10 letters or more in 18 (90%) out of 20 treated eyes and improved 15 letters or more in 14 (70%) out of 20 treated eyes. No treated eyes experienced a worsening of BCVA from baseline. The mean FCT (+/- SD) at baseline was 223 (+/- 47.43) microns. At 12 months after treatment, the mean FCT (+/- SD) reduced to 206 (+/- 50.87) microns. This reduction in FCT after treatment was not statistically significant (P = .11). At 12 months follow-up, absence of fluorescein leakage from the CNV was demonstrated in 19 (95%) out of 20 treated eyes and persistent leakage in one eye (5%). None of the 19 eyes that had CNV closure experienced recurrence at 12-month follow-up. No ocular or systemic adverse effects from treatment were encountered.These results of intravitreal bevacizumab in myopic CNV are very promising with no apparent short-term safety concerns. At 12 months, treated eyes had a significant improvement in visual acuity (VA). OCT findings, as well, showed a trend consistent with the beneficial changes observed for VA. Treatment resulted in complete absence of angiographic leakage in 95% of eyes. Further studies will be needed to better determine long-term efficacy and safety." @default.
• W2012138315 created "2016-06-24" @default.
• W2012138315 creator A5053092054 @default.
• W2012138315 creator A5060100077 @default.
• W2012138315 creator A5060222957 @default.
• W2012138315 creator A5024164426 @default.
• W2012138315 date "2009-01-01" @default.
• W2012138315 modified "2023-09-27" @default.
• W2012138315 title "Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results" @default.
• W2012138315 cites W110906275 @default.
• W2012138315 cites W115342157 @default.
• W2012138315 cites W1965259073 @default.
• W2012138315 cites W1988233478 @default.
• W2012138315 cites W1993747607 @default.
• W2012138315 cites W1999611557 @default.
• W2012138315 cites W2001950796 @default.
• W2012138315 cites W2007761826 @default.
• W2012138315 cites W2012868839 @default.
• W2012138315 cites W2012906786 @default.
• W2012138315 cites W2015843817 @default.
• W2012138315 cites W2020050260 @default.
• W2012138315 cites W2023874692 @default.
• W2012138315 cites W2026626516 @default.
• W2012138315 cites W2031725950 @default.
• W2012138315 cites W2039446733 @default.
• W2012138315 cites W2048182953 @default.
• W2012138315 cites W2051193332 @default.
• W2012138315 cites W2051258987 @default.
• W2012138315 cites W2055385676 @default.
• W2012138315 cites W2069895573 @default.
• W2012138315 cites W2085712747 @default.
• W2012138315 cites W2107751384 @default.
• W2012138315 cites W2116554707 @default.
• W2012138315 cites W2124415048 @default.
• W2012138315 cites W2138421229 @default.
• W2012138315 cites W2153632706 @default.
• W2012138315 cites W2155905635 @default.
• W2012138315 cites W2166926836 @default.
• W2012138315 cites W233579014 @default.
• W2012138315 cites W2581767635 @default.
• W2012138315 cites W2748001554 @default.
• W2012138315 cites W4237695591 @default.
• W2012138315 cites W4361866471 @default.
• W2012138315 doi "https://doi.org/10.1016/j.ajo.2008.07.022" @default.
• W2012138315 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18774547" @default.
• W2012138315 hasPublicationYear "2009" @default.
• W2012138315 type Work @default.
• W2012138315 sameAs 2012138315 @default.
• W2012138315 citedByCount "106" @default.
• W2012138315 countsByYear W20121383152012 @default.
• W2012138315 countsByYear W20121383152013 @default.
• W2012138315 countsByYear W20121383152014 @default.
• W2012138315 countsByYear W20121383152015 @default.
• W2012138315 countsByYear W20121383152016 @default.
• W2012138315 countsByYear W20121383152017 @default.
• W2012138315 countsByYear W20121383152018 @default.
• W2012138315 countsByYear W20121383152019 @default.
• W2012138315 countsByYear W20121383152021 @default.
• W2012138315 countsByYear W20121383152022 @default.
• W2012138315 crossrefType "journal-article" @default.
• W2012138315 hasAuthorship W2012138315A5024164426 @default.
• W2012138315 hasAuthorship W2012138315A5053092054 @default.
• W2012138315 hasAuthorship W2012138315A5060100077 @default.
• W2012138315 hasAuthorship W2012138315A5060222957 @default.
• W2012138315 hasConcept C118487528 @default.
• W2012138315 hasConcept C120665830 @default.
• W2012138315 hasConcept C121332964 @default.
• W2012138315 hasConcept C134018914 @default.
• W2012138315 hasConcept C141071460 @default.
• W2012138315 hasConcept C188816634 @default.
• W2012138315 hasConcept C2776694085 @default.
• W2012138315 hasConcept C2776694393 @default.
• W2012138315 hasConcept C2777093970 @default.
• W2012138315 hasConcept C2777802072 @default.
• W2012138315 hasConcept C2778257484 @default.
• W2012138315 hasConcept C2779829184 @default.
• W2012138315 hasConcept C2780248432 @default.
• W2012138315 hasConcept C2781359195 @default.
• W2012138315 hasConcept C555293320 @default.
• W2012138315 hasConcept C71924100 @default.
• W2012138315 hasConceptScore W2012138315C118487528 @default.
• W2012138315 hasConceptScore W2012138315C120665830 @default.
• W2012138315 hasConceptScore W2012138315C121332964 @default.
• W2012138315 hasConceptScore W2012138315C134018914 @default.
• W2012138315 hasConceptScore W2012138315C141071460 @default.
• W2012138315 hasConceptScore W2012138315C188816634 @default.
• W2012138315 hasConceptScore W2012138315C2776694085 @default.
• W2012138315 hasConceptScore W2012138315C2776694393 @default.
• W2012138315 hasConceptScore W2012138315C2777093970 @default.
• W2012138315 hasConceptScore W2012138315C2777802072 @default.
• W2012138315 hasConceptScore W2012138315C2778257484 @default.
• W2012138315 hasConceptScore W2012138315C2779829184 @default.
• W2012138315 hasConceptScore W2012138315C2780248432 @default.
• W2012138315 hasConceptScore W2012138315C2781359195 @default.
• W2012138315 hasConceptScore W2012138315C555293320 @default.
• W2012138315 hasConceptScore W2012138315C71924100 @default.
• W2012138315 hasIssue "1" @default.
• W2012138315 hasLocation W20121383151 @default.

• next